Overview
Moderna biotechnology network - usage, trials and safety telemetry aggregated from public APIs.
Sponsored studies
144
17 currently recruiting
Enrolment target
67.2M
summed across all registered studies
Countries
53
1,134 trial cities geocoded
Phase 3 studies
29
179 distinct interventions
FAERS safety reports
796
openFDA · Spikevax product reports
MRNA share price
$218.01
+738.2% over 12 months
Newest announced program - intismeran autogene
2026-08-19
Announced today, 19 August 2026: Merck and Moderna reported that the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its co-primary endpoints of recurrence-free survival and distant metastasis-free survival at a pre-specified interim analysis in adjuvant high-risk melanoma - the first individualised mRNA cancer therapy to clear a confirmatory Phase 3.
ProgramIntismeran autogene (mRNA-4157 / V940) + KEYTRUDA
IndicationAdjuvant treatment of completely resected high-risk melanoma (Stage IIB-IV); individualised neoantigen therapy
Pivotal trialNCT05933577
Participants randomised1,089
Trial sites165
Registry statusactive not recruiting
Registry update stream
- 2026-10-16NCT06623422 · recruiting · A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants Wi
- 2026-10-13NCT06880549 · recruiting · A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents i
- 2026-10-13NCT07870330 · not yet recruiting · A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Child
- 2026-10-09NCT07513376 · recruiting · A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With B
- 2026-10-08NCT06508320 · completed · A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes
- 2026-10-07NCT07863635 · not yet recruiting · A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formula
- 2026-10-06NCT07279766 · completed · Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adu
- 2026-10-01NCT06833073 · recruiting · A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/I